精彩内容日前，国家药监局官网显示，江苏康缘药业的恩格列净片、成都康弘药业的依帕司他片等糖尿病药同日获批。米内网数据显示，糖尿病用药（化+生）在2025年上半年中国零售药店终端销售额同比增长超过10%。从TOP20来看，药王“易主”，独家注射剂暴涨3180%，扬子江药业、甘李药业上榜。今年以来，糖尿病用药已有超过40个品种报产在审，其中，7个为新药，涉及恒瑞医药、东阳光药、华东医药等企业。康缘、康弘...
Source Link精彩内容日前，国家药监局官网显示，江苏康缘药业的恩格列净片、成都康弘药业的依帕司他片等糖尿病药同日获批。米内网数据显示，糖尿病用药（化+生）在2025年上半年中国零售药店终端销售额同比增长超过10%。从TOP20来看，药王“易主”，独家注射剂暴涨3180%，扬子江药业、甘李药业上榜。今年以来，糖尿病用药已有超过40个品种报产在审，其中，7个为新药，涉及恒瑞医药、东阳光药、华东医药等企业。康缘、康弘...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.